APMA Asks MACs to Cease Adverse Actions on Amniotic Injections and Provide Clarification | News | APMA
APMA Asks MACs to Cease Adverse Actions on Amniotic Injections and Provide Clarification

APMA Asks MACs to Cease Adverse Actions on Amniotic Injections and Provide Clarification Members Only Content

On March 11, APMA sent a request to all Part B Medicare Administrative Contractors (MACs) about its concerns with their announcement in late February that Medicare does not cover manipulated amniotic and/or placental tissue biologics for injections to treat illness for claims with dates of services on or after December 6, 2019.

This content is available to APMA members only. If you are a member, please log in to see the full content.



Related Resources

New Skin Substitute Policies Not Taking Effect

Learn More

Skin Substitute Policies Effective Date Delayed

Learn More

ADVERTISEMENT
All your coding questions answered in one convenient, online resource. subscribe today!